Aquestive Therapeutics stock target raised to $8 following FDA wishes By Investing.com

© Reuters.

On Wednesday, Lake Street Capital Markets adjusted its outlook. a mysterious cure (NASDAQ:), the pharmaceutical company raised its price target on its stock. A new stock target has been set at $8.00, a significant increase from the previous $3.00, and a Buy rating is maintained on the stock.

The adjustment comes in anticipation of a potentially eventful year for Aquestive Therapeutics. The company is awaiting the FDA’s decision on its epilepsy drug Libervant, with approval expected in April. Additionally, Aquestive is preparing to submit a New Drug Application (NDA) for Anaphylm, a treatment for severe allergic reactions, by the end of this year.

The company recently reported fourth quarter 2024 revenue of $13.2 million. That figure surpassed Lake Street Capital Markets’ estimate of $11.8 million. Increased sales and the likelihood of achieving future goals contributed to the optimistic rating and price target revisions.

Analysts at Lake Street Capital Markets weighed in on the company’s outlook, saying, “Libervant’s potential April FDA approval and Anaphylm’s expected NDA submission set the stage for an eventful 2024, both of which are significant value-creating events.” expressed confidence in it. This sentiment highlights the company’s positive view of Aquestive Therapeutics’ near-term opportunities.

Investors and market observers will be closely monitoring Aquestive Therapeutics as it navigates important regulatory milestones that could have a notable impact on the company’s valuation and market performance.

This article was sponsored by AI and reviewed by an editor. Please see our T&Cs for more details.